NGM Biopharmaceuticals In... (NGM)
NASDAQ: NGM
· Real-Time Price · USD
1.54
-0.02 (-1.28%)
At close: Apr 03, 2024, 3:59 PM
NGM Biopharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 4.42M | 22.43M | 29.76M | 36.63M | 55.33M | 58.11M | 68.78M | 77.25M | 77.88M | 76.69M | 81.6M | 84.58M |
Cost of Revenue | 3.26M | 3.85M | 4.44M | 4.72M | 3.61M | 2.49M | 1.4M | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 1.16M | 18.58M | 25.32M | 31.91M | 51.73M | 55.62M | 67.38M | 77.25M | 77.88M | 76.69M | 81.6M | 84.58M |
Operating Income | -151.46M | -160.1M | -177.37M | -183.86M | -166.25M | -155.18M | -135.88M | -125.43M | -120.69M | -121.14M | -122.09M | -111.01M |
Interest Income | 9.32M | 9.31M | 8.03M | 6.12M | 3.71M | 1.77M | 910K | 482K | 420K | 451K | 605K | 878K |
Pretax Income | -142.38M | -151.14M | -169.61M | -177.86M | -162.67M | -153.46M | -135.07M | -125.24M | -120.33M | -121.09M | -121.99M | -110.92M |
Net Income | -139.83M | -146.74M | -164.16M | -171.87M | -159.09M | -151.74M | -134.39M | -125.11M | -120.33M | -121.09M | -121.99M | -110.92M |
Selling & General & Admin | 37.84M | 39.66M | 41.1M | 41.38M | 40.52M | 40.21M | 38.97M | 38.87M | 36.87M | 34.79M | 32.38M | 29.36M |
Research & Development | 117.52M | 142.87M | 166.04M | 179.12M | 181.07M | 173.07M | 165.68M | 163.82M | 161.71M | 163.04M | 171.31M | 166.23M |
Other Expenses | -234K | -356K | -263K | -124K | -132K | -57K | -100K | -292K | -60K | -399K | -502K | -315K |
Operating Expenses | 155.36M | 182.53M | 207.13M | 220.49M | 221.58M | 213.29M | 204.65M | 202.69M | 198.58M | 197.83M | 203.69M | 195.59M |
Interest Expense | 2.55M | 2.03M | 3M | 3.54M | 3.71M | 1.68M | 719K | 176K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 155.88M | 182.53M | 207.13M | 220.49M | 221.58M | 213.29M | 204.65M | 202.69M | 198.58M | 197.83M | 203.69M | 195.59M |
Income Tax Expense | -2.55M | -4.41M | -5.45M | -6M | -3.58M | -1.72M | -785K | -352K | -335K | -335K | -489K | -374K |
Shares Outstanding (Basic) | 82.8M | 82.71M | 82.46M | 82.01M | 81.79M | 80.62M | 79.27M | 78.02M | 77.78M | 77.41M | 77.1M | 76.03M |
Shares Outstanding (Diluted) | 82.8M | 82.71M | 82.46M | 82.01M | 81.79M | 80.62M | 79.27M | 78.02M | 77.78M | 77.41M | 77.1M | 76.03M |
EPS (Basic) | -1.69 | -1.78 | -2 | -2.12 | -1.98 | -1.91 | -1.71 | -1.61 | -1.56 | -1.61 | -1.67 | -1.57 |
EPS (Diluted) | -1.69 | -1.78 | -2 | -2.12 | -1.98 | -1.91 | -1.71 | -1.61 | -1.56 | -1.61 | -1.67 | -1.57 |
EBITDA | -149.85M | -159M | -176.21M | -181.87M | -162.83M | -151.75M | -131.56M | -120.95M | -116.08M | -116.53M | -117.36M | -106.18M |
EBIT | -96.73M | -106.01M | -121.28M | -126.68M | -158.95M | -124.55M | -107.26M | -97.9M | -93.47M | -93.47M | -94.42M | -83.33M |
Depreciation & Amortization | 2.22M | 2.32M | 2.38M | 3.22M | 4.04M | 4.9M | 5.79M | 5.96M | 6.09M | 6.16M | 6.29M | 6.38M |